CP
The startup develops virtual drugs aimed at treating vascular dysfunction and shock, utilizing a novel approach that minimizes the risks associated with fluid overload and the toxicities of traditional catecholamine-based vasoactive agents. This technology provides essential supportive therapy during critical hemodynamic instability, enhancing patient safety and treatment efficacy.
Cambridge, United Kingdom
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops virtual drugs aimed at treating vascular dysfunction and shock, utilizing a novel approach that minimizes the risks associated with fluid overload and the toxicities of traditional catecholamine-based vasoactive agents. This technology provides essential supportive therapy during critical hemodynamic instability, enhancing patient safety and treatment efficacy.